Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://t.co/vWJrUN9C0H

MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/8zJ0OBWjbm

If COVID was responsible for causing autoimmune Dz (AD), it is possible that Molecular mimicry was in play. Study shows 10nsequence homology between SARS-CoV-2 & AD epitopes; 2) similar MHC binding; 3) of high empirical immunogenicity. https://t.co/WO3gjxhVBw https://t.co/QdqtQMHcpL

Researchers have developed a machine learning model capable of predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis. In the KURAMA cohort of 210 SN patients, 57 (27%) progressed to RA. The FNN model excelled with an AUC of 0.924 and 81% https://t.co/b8G2AzMZ7m

Phase 3 RCT shows that SC Abatacept was not effective in treating Active Idiopathic Inflammatory Myopathy: 148 (double-blind) & 133 (OL) pts Rx for 24wks with similar improvement 56% ABA vs 42.5% PBO (P = 0.083); NS at 52 wks & w/ dermatomyositis. https://t.co/InlHJSmiKn https://t.co/mtFQWp3vlb

EUSTAR database study of 17,805 scleroderma (SSc) pts, 468 (2.6%) used HCQ with no effect on or improvement on HAQ-DI, or hand function scores when comparing HCQ users to non-HCQ users. https://t.co/Tu4tfG74pn https://t.co/Kckx3zTiJ4

Fresenius Receives FDA Approval for their Denosumab Biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) based on reference products: Prolia (denosumab) and Xgeva (denosumab) respectively. US launch mid-2025 https://t.co/0i5ZMJSxnp https://t.co/zeQ7QhmA0n

Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk

Full read review on inflammatory myositis (Patient or med student level knowlegdge) Epidemiology Risk Factors Prognosis Sxs, Dx, Differential Dx Treatment Complications Myositis Guidelines https://t.co/s0LtHyYeuS https://t.co/lMEpMIotSP

Missed RheumNow Live but still want the great coverage? For the first time ever, https://t.co/4UQlqwujiR 2025 is Available On Demand! ✔️ STEP Talks from top rheumatologists ✔️ Lectures on the biggest clinical challenges ✔️ Speaker slides and handouts you’ll use Non-CME, https://t.co/lns8EQBZjw

Worse Outcomes in HLA-B27+ JIA Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term outcomes, including lower rates of drug-free remission, in a prospective Scandinavian study. https://t.co/VEKqHvO1qw https://t.co/49y0JQL0Gr

Peripheral Nerve Blocks for Hip Fractures JAMA reviews the use of peripheral nerve block with hip fractures as an effective pain management strategy that can be performed by credentialed clinicians outside of the operating room. https://t.co/baeLWVxeUo https://t.co/ZBTVDT0jGR